Independence Blue Cross Restricts Weight Loss Drug Coverage Starting January 1, 2025, Independence Blue Cross (IBX), the largest health insurer in southeastern Pennsylvania, will no longer cover certain weight loss medications, including GLP-1 receptor agonists like Wegovy and Ozempic, when prescribed solely for managing weight. The company will continue covering these medications for individuals with FDA-approved conditions such as Type 2 diabetes or cardiovascular disease. This change impacts both group and individual commercial plan holders, shifting the full cost of these drugs—ranging from $700 to $1,350 per month—to patients who…
Read MoreTag: Ozempic
The High Cost of Health: Who Gets Weight Loss Prescriptions?
Disparities in Weight Loss Prescriptions The disparity in access to medications like Wegovy, Rybelsus, and Ozempic highlights a significant issue within the U.S. healthcare system. Despite the increasing medical applications of these drugs, which include managing diabetes and potentially preventing heart disease and stroke, many insurers remain reluctant to cover them for weight loss. Medicare, for example, is legally barred from covering weight-loss drugs unless the patient presents serious health risks. This limitation leaves over two-fifths of American adults who are obese but otherwise healthy without coverage options. Federal spending…
Read More